Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
While CDK4/6 inhibitors improved clinical outcomes in HR+HER2- metastatic breast cancer (MBC), resistance invariably occurs. The underlying molecular mechanisms are not actionable, leaving limited therapeutic options for progressing patients. Recent data highlight a role for IL-6 in the resistance of HR+HER2- MBC to CDK4/6 inhibition, potentially opening novel avenues forward.
Lung cancer screening by low-dose computed tomography reduces lung cancer mortality, but reliable risk-based selection of participants is crucial to maximize benefits and minimize harms. Multiple risk models have been developed for this purpose, and their discrimination and calibration performance is commonly evaluated based on large-scale cohort studies. Using a recent comparative evaluation of 10 risk models as an example, we illustrate the merits, limitations and pitfalls of such evaluations.
Hippocrates (Kos, c.460–c.370 BC) reminds us that “It is more important to know what sort of person has a disease than to know what sort of disease a person has”. This is still true today and reflects the emerging role of personalized medicine for patient-specific risk stratification and treatment programs. This report documents my personal experience as a patient with aggressive prostate cancer, who, as a scientist, had the privilege to access cutting-edge medical care and molecular profiling.
